EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients

Keiichi Hiraoka, Masataka Tsuge iD, Michihiko Kawahara, Hatsue Fujino iD, Yasutoshi Fujii, Atsushi Ono iD, Eisuke Murakami iD, Tomokazu Kawaoka, Daiki Miki iD, C Nelson Hayes iD, Seiya Kashiyama, Sho Mokuda iD und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Keiichi Hiraoka und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B virus, Antiviral Agents, RNA, Viral. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) particles containing HBV RNA are secreted into the blood; these RNA-containing particles are non-infectious byproducts of the replication cycle and are distinct from mature, DNA-containing virions. The proportion of these particles increases during nucleoside/nucleotide analog therapy, but the clinical significance of serum HBV RNA remains unclear. We evaluated longitudinal changes in serum HBV RNA and their association with the antiviral efficacy of nucleoside/nucleotide analog therapy. Eighty-six patients with chronic HBV infection (baseline HBV DNA ≥ 5.0 Log IU/mL and ALT < 500 U/L) treated with entecavir (ETV, N = 80) or tenofovir alafenamide (TAF, N = 6) were included. Serum HBV RNA was quantified using Cobas HBV RNA (RUO) at baseline, week 12, and week 48. Associations with clinical variables and treatment response were analyzed. Baseline HBV RNA correlated with HBsAg, HBV DNA, and hepatitis B core-related antigen. Both HBV DNA and RNA tended to decrease with advanced liver fibrosis. HBV DNA and RNA declines did not differ between HBeAg-positive and -negative patients, but the HBV RNA/DNA ratio at week 48 was significantly higher in HBeAg-positive cases (p < 0.001). Patients with baseline ALT ≥ 100 U/L showed significantly lower RNA levels at weeks 12 and 48 (p = 0.004, p < 0.001). While HBV DNA decline was similar between ETV and TAF (p = 0.076), RNA decline was significantly greater with TAF at week 12 (p = 0.027). Serum HBV RNA reflects intrahepatic viral replication and may not be influenced by fibrosis progression. HBV RNA decline during nucleoside/nucleotide analog therapy differed between ETV and TAF, suggesting drug-specific effects on viral RNA dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B virusAntiviral AgentsRNA, ViralNucleosidesHumansMaleFemaleMiddle AgedAdultGuanineDNA, ViralTenofovirTreatment OutcomeAgedNucleotides

Stichwörter der Autor:innen

HBV DNAHBV RNAHBeAgHBsAgnucleotide/nucleoside analog

Substanzen

Antiviral AgentsRNA, ViralGuanineentecavirNucleosidesDNA, ViralTenofovirNucleotides

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
  • Liver Center, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
  • Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
  • Section of Clinical Laboratory, Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
  • Division of Laboratory Medicine, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
  • Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan.

ORCID-Profile: Masataka Tsuge, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, C Nelson Hayes, Sho Mokuda

Förderung

  • JSPS KAKENHI
  • Japan Agency for Medical Research and Development

Zitieren

APA

Hiraoka, K., Tsuge, M., Kawahara, M., Fujino, H., Fujii, Y., Ono, A., Murakami, E., Kawaoka, T., Miki, D., Hayes, C. N., Kashiyama, S., Mokuda, S., Yamazaki, S., & Oka, S. (2025). Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010141

Vancouver

Hiraoka K, Tsuge M, Kawahara M, Fujino H, Fujii Y, Ono A, et al. Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010141

BibTeX
@article{Hiraoka2025,
  author = {Hiraoka, Keiichi and Tsuge, Masataka and Kawahara, Michihiko and Fujino, Hatsue and Fujii, Yasutoshi and Ono, Atsushi and Murakami, Eisuke and Kawaoka, Tomokazu and Miki, Daiki and Hayes, C Nelson and Kashiyama, Seiya and Mokuda, Sho and Yamazaki, Shinichi and Oka, Shiro},
  title = {Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010141}
}
Kostenlos starten →